Kristleifur Kristjansson
Keine laufenden Positionen mehr
Profil
Kristleifur Kristjansson was the founder of deCODE genetics, Inc. where he held the title of Vice President-Clinical Affairs from 1995 to 2012.
He is also the founder of Skraeda ehf.
Kristleifur's former job was as the Executive Vice President-Research & Development at Össur hf from 2012 to 2022.
Dr. Kristjansson earned a doctorate degree from the University of Iceland.
Ehemalige bekannte Positionen von Kristleifur Kristjansson
| Unternehmen | Position | Ende |
|---|---|---|
| EMBLA MEDICAL HF. | Technik-/Wissenschafts-/F&E-Leiter | 01.07.2022 |
deCODE genetics, Inc.
 deCODE genetics, Inc. Pharmaceuticals: GenericHealth Technology deCODE genetics, Inc. is a bio-pharmaceutical company. It developing and marketing products to improve the treatment, diagnosis and prevention of common diseases. deCODE applies its capabilities in chemistry and structural biology to the development of drugs in major therapeutic areas, and applies its discoveries in human genetics to bring to market DNA-based reference laboratory tests and consumer genome analysis services to assess individual risk of common diseases. The company was founded by Kari Stefansson and Jeffrey Gulcher in August 1996 and is headquartered in Reykjavík, Iceland. | Gründer | 01.01.2012 |
| Skraeda ehf | Gründer | - |
Ausbildung von Kristleifur Kristjansson
| University of Iceland | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| EMBLA MEDICAL HF. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
deCODE genetics, Inc.
deCODE genetics, Inc. Pharmaceuticals: GenericHealth Technology deCODE genetics, Inc. is a bio-pharmaceutical company. It developing and marketing products to improve the treatment, diagnosis and prevention of common diseases. deCODE applies its capabilities in chemistry and structural biology to the development of drugs in major therapeutic areas, and applies its discoveries in human genetics to bring to market DNA-based reference laboratory tests and consumer genome analysis services to assess individual risk of common diseases. The company was founded by Kari Stefansson and Jeffrey Gulcher in August 1996 and is headquartered in Reykjavík, Iceland. | Health Technology |
| Skraeda ehf |
